Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib plus immune checkpoint inhibitor for FGFR1/2/3-altered advanced solid tumors
ChiCTR2400087522Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in Nonhematologic neoplasms, transitional cell carcinoma (TCC) and breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective response rate. Started Jul 2024; status: recruiting.
02
Drugs
pemigatinib
03
Conditions
Nonhematologic neoplasmstransitional cell carcinoma (TCC)breast cancer
Beyond the preview
Go deeper on ChiCTR2400087522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087522.